Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. - Wikidata - thesis-toulmin - TriplyDB

Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course.

Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course.

http://www.wikidata.org/entity/Q39808939

about

Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis B Cells and Autoantibodies in Multiple Sclerosis Stage-specific immune dysregulation in multiple sclerosis Biomarkers of therapeutic response in multiple sclerosis: current status Permeability of the blood-brain barrier predicts conversion from optic neuritis to multiple sclerosis Feasibility of the use of combinatorial chemokine arrays to study blood and CSF in multiple sclerosis Genomic regions associated with multiple sclerosis are active in B cells Reassessment of blood gene expression markers for the prognosis of relapsing-remitting multiple sclerosis Clinical, MRI, and CSF markers of disability progression in multiple sclerosis.Predicting optimal response to B-cell depletion with rituximab in multiple sclerosis using CXCL13 index, magnetic resonance imaging and clinical measures Regulated Production of CXCL13 within the Central Nervous System.Type-I interferons suppress microglial production of the lymphoid chemokine, CXCL13.Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammation.Detection of cerebral spinal fluid-associated chemokines in birth traumatized premature babies by chip-based immunoaffinity CE.Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis.Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers.Relationship between cerebrospinal fluid biomarkers for inflammation, demyelination and neurodegeneration in acute optic neuritis Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis.Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel.Complexity of the microglial activation pathways that drive innate host responses during lethal alphavirus encephalitis in mice.B Cell, Th17, and Neutrophil Related Cerebrospinal Fluid Cytokine/Chemokines Are Elevated in MOG Antibody Associated Demyelination.Vitamin D receptor binding, chromatin states and association with multiple sclerosis.CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation.Intravenous immunoglobulin treatment of the post-polio syndrome: sustained effects on quality of life variables and cytokine expression after one year follow up.Rituximab combination therapy in relapsing multiple sclerosis Targeting CXCL13 During Neuroinflammation Next-generation sequencing identifies microRNAs that associate with pathogenic autoimmune neuroinflammation in rats CXCL13 promotes isotype-switched B cell accumulation to the central nervous system during viral encephalomyelitis.Investigations on CXCL13 in anti-N-methyl-D-aspartate receptor encephalitis: a potential biomarker of treatment response.Novel CXCL13 transgenic mouse: inflammation drives pathogenic effect of CXCL13 in experimental myasthenia gravis.Diagnostic value of cytokines and chemokines in lyme neuroborreliosis.TGFβ regulates persistent neuroinflammation by controlling Th1 polarization and ROS production via monocyte-derived dendritic cells.CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions Emerging Approaches for Validating and Managing Multiple Sclerosis Relapse.The evidence for a role of B cells in multiple sclerosis.Neurofilaments as biomarkers in multiple sclerosis.B cells and antibodies in multiple sclerosis pathogenesis and therapy.Effects of CXCL13 inhibition on lymphoid follicles in models of autoimmune disease.The utility of cerebrospinal fluid analysis in patients with multiple sclerosis.Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies.

P2860

Q26770818-D298ACED-4B98-4D05-9C69-E361FEE97269 Q26801386-4A1A99FD-B1F1-43C3-B6AE-A51190659884 Q26852859-40F08BF0-D0D2-4AD8-AB38-70B8AFD0656C Q27012726-8B8E7AF0-4269-47AE-98D9-8E5FC3FF25B7 Q28265269-1A2A8CC7-A3EB-47D5-A863-F6201948B78A Q28535303-708D0FF0-8F08-4C05-86EF-C5BF3A18F110 Q28731577-3AC2F01E-5FD7-4891-A453-2C5CFD518BBC Q28740839-2ADCD15B-148F-427B-9DEC-C17080F9245C Q30712257-703CA368-FAEC-4251-820D-B088B41EA231 Q33692520-EF2D314E-64CA-4E4B-9AB1-89E562987221 Q33772300-C3804D67-4660-44B8-8B7A-4B4454897858 Q34083294-D8F9D01A-AEB2-467A-B9D7-82C861369322 Q34504952-766E84AD-5A6B-4DDC-BA7F-DB0DF5ECA41A Q34628101-2D3250BD-78A3-4C19-94DF-A6691AE05CFE Q34700673-817FEC47-4DDE-4388-BF8D-6409FD485CFC Q34718044-A838B417-CE15-4369-B0BE-F3508537EA32 Q35015106-E36E6B17-145E-44C5-B726-10310DD6FD2E Q35212994-F5C483D7-277B-49A2-97D8-C8B624C60715 Q35364112-C32C00A2-C11A-45A9-87F6-97870BAAF1AE Q35929137-A09D673A-23BD-42E4-8F9E-17647CEEE9F8 Q35937581-3B0BCF87-C773-4FCF-B075-B2CFD19729AE Q36122415-93EF0798-7B88-4FA7-9448-61A4B06D8B4B Q36161486-6FD1639F-2DF7-42E4-89CA-EE7EE2490002 Q36298920-5269F35F-8A93-4EC5-8E7E-66FCD44CFB8E Q36366897-86D0FB3D-D67B-4A4C-A3C6-F665B24D3874 Q36551188-EEA9C854-8D3F-467B-8885-37A5634C412D Q36748227-7B9B4696-0060-471D-822A-B44FAF2C4A9B Q36788638-307A5ADA-C477-4C0F-BCD6-D45204690E8C Q36813361-B4D7AB96-4B98-42D2-801A-FB3C955072C2 Q36946564-58F50D9C-5B02-4F39-9BA4-3DDF05FB22BC Q37252344-EBF1FBA2-FF37-4BBC-A6BA-A9288E78E00E Q37316413-CE27BC01-7A90-429B-B485-8814A8D1E7D2 Q37646434-1B1A2CC7-5560-4669-9356-5E27B454832B Q37729523-909B1885-A58D-4136-859A-3540CFE9B180 Q37993033-5339FFD2-4E63-4947-AD3D-91920537F21A Q38001602-CDC92A62-AFBD-4A36-8EFB-D4417618FA3A Q38050398-D3270236-CED4-4CE7-AF5F-C2C5FEE1824E Q38091729-35F655EA-5865-4427-BD83-D93EEC2B9D96 Q38092972-43196AF4-C110-4D28-A96A-C1600128582E Q38121632-D399630B-A3DE-4E1A-AA50-75ECA1FAACAF

P2860

Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course.

http://www.wikidata.org/entity/Q39808939

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

Cerebrospinal fluid CXCL13 in ...... marker for the disease course.

@en

Cerebrospinal fluid CXCL13 in ...... marker for the disease course.

@nl

type

label

Cerebrospinal fluid CXCL13 in ...... marker for the disease course.

@en

Cerebrospinal fluid CXCL13 in ...... marker for the disease course.

@nl

prefLabel

Cerebrospinal fluid CXCL13 in ...... marker for the disease course.

@en

Cerebrospinal fluid CXCL13 in ...... marker for the disease course.

@nl

P1433

Q39808939-E317E69F-3F53-4264-9CFF-7BC4AAD6C9FD

P1476

Q39808939-1B843881-4D02-4400-9B24-30663C95D79A

P2093

Q39808939-34280296-7460-4E90-82A9-4CD19BE12C58

Q39808939-412F8F3B-8F36-4926-B7B3-A361441E34A2

Q39808939-44CC76C7-9393-4625-94CF-288FF6E31F9D

Q39808939-8D8EA311-1A5B-41B1-8BB2-4525D3A9442A

Q39808939-8DBB9238-44C6-412F-B3E8-B342A563F23F

P2860

Q39808939-02CA65D0-FA0B-44D5-A3DD-C5FD9D29B4E3

Q39808939-147FAC59-A51C-424F-985A-AAA8398E69FF

Q39808939-275D19C4-461A-426C-B395-4418E1FFB93A

Q39808939-5178A8CF-ACF0-48C7-B158-E5A9BD73EDFB

Q39808939-668CF47E-8FB6-41A8-9479-7084DE39122A

Q39808939-6D4C9E1A-197F-45B8-92B2-73E34ACA2FA6

Q39808939-7807560C-ECDF-4826-BD47-85D4D5A8A1AF

Q39808939-85A4F8CD-1F25-4470-8846-44C0504E62B6

Q39808939-8F2FB2F3-2983-46BF-9F3A-A746BF713D18

Q39808939-8FC6654D-DF32-49EA-A4A0-104960EE3311

P304

Q39808939-97214FB3-2961-4587-9F72-13DDBFB9FED2

P31

Q39808939-54C98CCC-167B-4D8A-A883-5A4052E64D26

P356

Q39808939-9B48A41D-99F3-46AE-AF5F-37BE91A3D0AF

P433

Q39808939-88F91329-850B-4CF8-85C4-8137E0B10EA2

P478

Q39808939-96092DE6-88D9-4010-B140-F189E26BD573

P50

Q39808939-22D17049-67EE-44D5-B471-7DC04818349F

Q39808939-3975DC7C-BD45-4611-B8D3-C0438A944A8B

Q39808939-4B2E6623-3394-43F2-8982-0FD62EA02017

Q39808939-5BA2E4C5-70A8-4EBB-ADA3-E43D0F9A36B0

Q39808939-BBABFFBF-6EB8-4068-AF5D-75D0B58ABD84

P577

Q39808939-A68D23B6-BA27-4202-8D9B-D7B528BCB3BE

P5875

Q39808939-704555A7-F3A1-4FD7-93DE-886F25A83CA4

P698

Q39808939-D63327BA-A912-4878-A5D7-41A0B4BDB35F

P921

Q39808939-E3A94AE4-2E64-4C8B-B07D-5157A141AE2D

Q39808939-EC359D46-90B3-4625-B129-664718B97E76

P356

1352458510389102

P1433

Multiple Sclerosis Journal

P1476

Cerebrospinal fluid CXCL13 in ...... marker for the disease course

@en

P2093

Ellen Iacobaeus

http://www.w3.org/2001/XMLSchema#string

Fredrik Piehl

http://www.w3.org/2001/XMLSchema#string

Jan Hillert

http://www.w3.org/2001/XMLSchema#string

Magnus L Andersson

http://www.w3.org/2001/XMLSchema#string

Tomas Olsson

http://www.w3.org/2001/XMLSchema#string

P2860

Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

Borrelia garinii induces CXCL13 production in human monocytes through Toll-like receptor 2

Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis

Multiple sclerosis

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

Multiple sclerosis

Differential diagnosis of suspected multiple sclerosis: a consensus approach

The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS).

Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.

P304

335-343

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1352458510389102

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Finn Sellebjerg

P577

2010-12-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49661540

http://www.w3.org/2001/XMLSchema#string

P698

21135023

http://www.w3.org/2001/XMLSchema#string

P921

cerebrospinal fluid

multiple sclerosis